Join the Oncology Brothers podcast as they dive into the highlights from ASCO 2024 with special guest Dr. Erika Hamilton, a breast medical oncologist from the Sarah Cannon Research Institute. In this episode, they discuss key abstracts in the world of breast cancer, including updates on RxPonder, PostMonarch, INAVO120, DESTINY-Breast06, and the Emerald Trial. Dr. Hamilton provides valuable insights on biomarker testing, CDK4/6 inhibitors, and groundbreaking advancements in HER2-targeted therapies. Discover how these studies are shaping treatment strategies for hormone receptor positive, HER2-low, and HER2-positive breast cancer patients. Don't miss out on this informative discussion packed with practical insights for community oncologists. Stay tuned for more ASCO 2024 highlights from the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Oncology Brothers: Practice-Changing Cancer Discussions